Linking NYS Cancer Registry Data to Medicare, Medicaid and Hospital Discharge Files to Assess Breast and Colorectal Cancer Care

<p>The State of New York collects vast amounts of data to monitor the health of its citizens and administer public health programs. Traditionally these programs have worked independently, with limited collaboration or data sharing. Our broader project seeks to bring diverse sources of data and expertise together to examine the quality of cancer care delivery, from early detection to survival, with an emphasis on breast and colorectal cancer. To accomplish this, we are undertaking a historic linkage between the New York State Cancer Registry, the New York State Medicaid Program, statewide hospital discharge data (SPARCS), and federal Medicare claims data. Each of these data sources contains distinctive information not present in the other sources, yielding a whole that is greater than the sum of its parts. This poster presents preliminary results from the initial linkage which highlight the differences between the Medicaid and non-Medicaid populations.</p

Kaplan-Meier Curves of Progression-Free Survival (PFS) and Overall Survival (OS) Distributions after Vandetanib with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients.

<p><b>A</b>, PFS distribution for all patients (n = 27). <b>B</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20). <b>C</b>, PFS distribution for all patients (n = 27). <b>D</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20).</p

Study CONSORT Flow Diagram.

<p>Study CONSORT Flow Diagram.</p

Pre-treatment values and fold-changes in plasma biomarkers after treatment with vandetanib and cetuximab (days 8 and 15) and with vandetanib, cetuximab and irinotecan (day 21, cycle 3 and cycle 5) in metastatic colorectal cancer patients.

<p>Data are shown as medians and interquartile ranges (in square brackets) compared to baseline levels. <i>P</i>-values are from the exact paired Wilcoxon test, before and after adjustment for multiple comparisons over time using the method of Genovese at al. VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; PlGF, placental growth factor; sVEGFR-1, soluble VEGF receptor-1; sVEGFR-2, soluble VEGF receptor-2; SDF-1α, stromal cell-derived factor-1-alpha; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha.</p

Waterfall Plot.

<p>Best response analysis after vandetanib with cetuximab and irinotecan limited to patients with confirmed KRAS wild-type metastatic colorectal cancer and at least 1 restaging imaging scan.</p

Adverse Events (based on worse toxicity by patient).

*<p>includes magnesium, potassium, sodium and calcium changes.</p